Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Total Debt (2017 - 2025)

Historic Total Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Q3 2025 value amounting to $312.9 million.

  • Ani Pharmaceuticals' Total Debt fell 223.45% to $312.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.9 million, marking a year-over-year decrease of 223.45%. This contributed to the annual value of $318.3 million for FY2024, which is 713.43% up from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Total Debt is $312.9 million, which was down 223.45% from $314.7 million recorded in Q2 2025.
  • Ani Pharmaceuticals' Total Debt's 5-year high stood at $320.1 million during Q3 2024, with a 5-year trough of $183.4 million in Q1 2021.
  • Its 5-year average for Total Debt is $284.3 million, with a median of $287.4 million in 2021.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Total Debt plummeted by 827.29% in 2021, and later soared by 5655.45% in 2022.
  • Over the past 5 years, Ani Pharmaceuticals' Total Debt (Quarter) stood at $287.4 million in 2021, then fell by 0.3% to $286.5 million in 2022, then grew by 3.69% to $297.1 million in 2023, then grew by 7.13% to $318.3 million in 2024, then decreased by 1.68% to $312.9 million in 2025.
  • Its Total Debt stands at $312.9 million for Q3 2025, versus $314.7 million for Q2 2025 and $316.5 million for Q1 2025.